ArticleFrontiers in cardiovascular medicine2026
Prognostic value of echocardiography-estimated right atrial pressure beyond the MAGGIC risk score in heart failure patients.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Venous congestion plays a central role in the pathophysiology of heart failure (HF). Echocardiography-estimated right atrial pressure (eRAP) provides a readily available non-invasive estimate of right-sided filling pressure and systemic venous congestion. However, it remains unclear whether eRAP can serve as a predictor of all-cause mortality in HF, and whether it can provide prognostic information beyond the scope of existing clinical risk assessments. Objective: This study investigated the association between eRAP and all-cause mortality in patients hospitalized for HF and evaluated its incremental prognostic value beyond the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score. Methods: This retrospective cohort study included 546 patients hospitalized for HF between January 2021 and December 2024. Patients were categorized as having normal (0-5 mmHg), borderline (5-10 mmHg), or elevated eRAP (10-20 mmHg) according to inferior vena cava (IVC) diameter and inspiratory collapsibility. The primary endpoint was all-cause mortality, with cardiovascular death and HF rehospitalization as secondary endpoints. Cox regression was used to evaluate the association between eRAP and all-cause mortality after adjustment for the MAGGIC risk score. The incremental prognostic value of eRAP beyond MAGGIC was assessed using discrimination, calibration, and decision-curve measures. Results: During the follow-up period of 1,187.7 person-years, 232 deaths occurred. After adjustment for the MAGGIC risk score, patients in borderline eRAP group and elevated eRAP group had a significantly higher risk of the primary endpoint than those in normal eRAP group (borderline vs. normal: HR 1.47, 95% CI 1.09-1.99, Conclusion: eRAP was independently associated with all-cause and cardiovascular mortality in hospitalized patients with HF and provided modest incremental prognostic information beyond the MAGGIC risk score.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.